Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

A Positive Reaction to RBI's Status Quo
Tue, 7 Jun Closing

After witnessing buying interest in the post-noon trading session, the Indian equity markets continued their momentum and closed the day on a firm note. Most of the buying interest was seen after the RBI kept the benchmark repo rate unchanged at 6.5%. Stocks from sectors such as banking, consumer durables and realty led the gains.

The BSE Sensex closed higher by about 232 points (up 0.9%). The NSE Nifty ended higher by about 65 points (up 0.8%). The BSE Mid Cap ended higher by 0.3%, while the BSE Small Cap ended higher by about 1%.

On the global front, most of the Asian indices closed their day on a positive note. Hong Kong's Hang Seng ended higher by 1.42%, while Japan's Nikkei 225 closed with gains of 0.58%. The European indices also witnessed buying interest. The FTSE 100 was up 0.47%, France's CAC 40 gained 1.18% and Germany's DAX was up 1.66%. The rupee was trading at Rs 66.75 to the dollar at the time of writing.

Pharma stocks are trading mixed with IPCA Labs and Ajanta Pharma leading the gains. As per a leading financial daily, Gavis Pharmaceutical LLC, the US arm of Lupin Ltd has received a final nod from the US health regulator to launch Voriconazole tablets. The drug is used to treat infections in skin, abdomen, kidney, bladder wall and wounds.

Vfend tablets and Vfend oral suspension had sales of US$ 92.8 million and US$ 15.9 million, respectively in the US as at the end of FY16.

The company has stated that it shall commence marketing the drug in the US shortly.

Many companies including the likes of Ajanta Pharma and Zydus Cadila Pharma have received US FDA approvals to sell this drug. Hence, the competition seems to be tough in this segment.

Lupin is an India-based transnational pharmaceutical company. It is engaged in manufacturing and marketing of branded and generic formulations, and active pharmaceutical ingredients (APIs). The Mumbai-based firm has launched 9 products in the US market and received approvals for 20 products from the USFDA so far this fiscal. On an overall basis, over 160 product filings are pending for approval with the USFDA between Lupin and Gavis together. Lupin has a portfolio of 124 products in the US market.

Stock of Lupin closed the day up by around 1.3%.

Moving on to the news form the banking space. Axis Bank has raised US$ 500 million at the London stock exchange through the issue of green bonds. Green bonds are a relatively new asset class carrying a lower coupon rate and are a cheap source of finance.

The proceeds from the bonds will be invested in renewable energy, transportation and infrastructure projects. The notes have been issued at a price of 99.479 at a yield of 2.9%.

Talking about renewables, government has an ambitious target of 100 gigawatt (GW) solar energy by 2022. The funds raised could help to achieve this mammoth goal.

Now, here's a market update from our friends over at The Daily Profit Hunter...

Bank Nifty opened on a positive note at 17,796 ahead of the RBI credit policy announcement. It traded on a mildly positive note in the first half but took off post noon. It even managed to cross the 18,000 mark during the day. The index ended the day with gains of 1.56% at 17,946. We will now have to wait and watch whether bulls are able to take out the resistance of 18,000 immediately or are held back.

Bank Nifty Touches 8-Month High of 18,000

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "A Positive Reaction to RBI's Status Quo". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 23, 2018 (Close)